Sangamo showcases progress in our pre-clinical programs at ASGCT.


Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease

BRISBANE, Calif. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 29, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties have entered into a definitive license agreement for a potential treatment of